SCHEMBL3769355

SCHEMBL3769355

Cc1ccc2c(Nc3ccc4c(c3)NC(=O)[C@@H]4C)nccc2c1Nc1ncccc1-c1ncnc2[nH]ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 9/20 0.49
RAF1 P04049 1/20 0.49
KDR P35968 14/20 0.49
LCK P06239 7/20 0.49
TEK Q02763 7/20 0.49
MAPK14 Q16539 3/20 0.44
PIK3CA P42336 1/20 0.36
TTBK1 Q5TCY1 1/20 0.36
TTBK2 Q6IQ55 1/20 0.36
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35
ABL1 P00519 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
MET P08581 1/20 0.35
PDGFRB P09619 1/20 0.35
PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770500 0.84 BRAF (0.50) BRAFRAF1KDRLCKTEK
SCHEMBL3643339 0.84 BRAF (0.52) BRAFRAF1KDRLCKTEK
SCHEMBL3647099 0.82 BRAF (0.53) BRAFRAF1KDRLCKTEK
SCHEMBL3778703 0.82 BRAF (0.53) BRAFRAF1KDRLCKTEK
SCHEMBL3777064 0.79 BRAF (0.49) BRAFRAF1KDRLCKTEK
SCHEMBL2516044 0.79 BRAF (0.65) BRAFRAF1KDRLCKTEK
SCHEMBL3643127 0.78 BRAF (0.51) BRAFRAF1KDRLCKTEK
SCHEMBL3637785 0.78 BRAF (0.48) BRAFRAF1KDRLCKTEK
SCHEMBL3645004 0.76 BRAF (0.55) BRAFRAF1KDRLCKTEK
SCHEMBL3641578 0.74 KDR (0.53) BRAFRAF1KDRLCKTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005198-A1 RAF KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2014-01-02 US claimed
US-20100324047-A1 RAF KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2010-12-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324047-A1 RAF KINASE MODULATORS AND METHODS OF USE BRAF, RAF1, ARAF BRAF 1/4885RAF1 2/4885KDR 700/4885
US-20140005198-A1 RAF KINASE MODULATORS AND METHODS OF USE BRAF, RAF1, ARAF BRAF 1/4885RAF1 2/4885KDR 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.